These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 21533543)
1. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Vemulapalli S; Mita A; Alvarado Y; Sankhala K; Mita M Target Oncol; 2011 Mar; 6(1):29-39. PubMed ID: 21533543 [TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859 [TBL] [Abstract][Full Text] [Related]
3. Updating progress in sarcoma therapy with mTOR inhibitors. Blay JY Ann Oncol; 2011 Feb; 22(2):280-7. PubMed ID: 20591820 [TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin: a new molecular target for breast cancer. Mita MM; Mita A; Rowinsky EK Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941 [TBL] [Abstract][Full Text] [Related]
5. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Iwenofu OH; Lackman RD; Staddon AP; Goodwin DG; Haupt HM; Brooks JS Mod Pathol; 2008 Mar; 21(3):231-7. PubMed ID: 18157089 [TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin as a target in hematological malignancies. Kelly KR; Rowe JH; Padmanabhan S; Nawrocki ST; Carew JS Target Oncol; 2011 Mar; 6(1):53-61. PubMed ID: 21499765 [TBL] [Abstract][Full Text] [Related]
7. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Carraway H; Hidalgo M Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929 [TBL] [Abstract][Full Text] [Related]
8. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936 [TBL] [Abstract][Full Text] [Related]
9. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of mTOR inhibitor resistance in cancer therapy. Carew JS; Kelly KR; Nawrocki ST Target Oncol; 2011 Mar; 6(1):17-27. PubMed ID: 21547705 [TBL] [Abstract][Full Text] [Related]
11. Current status and challenges associated with targeting mTOR for cancer therapy. Dowling RJ; Pollak M; Sonenberg N BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650 [TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020 [TBL] [Abstract][Full Text] [Related]
13. New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Agulnik M Cancer; 2012 Mar; 118(6):1486-97. PubMed ID: 21837674 [TBL] [Abstract][Full Text] [Related]
14. The role of mTOR inhibitors for treatment of sarcomas. Mita MM; Tolcher AW Curr Oncol Rep; 2007 Jul; 9(4):316-22. PubMed ID: 17588357 [TBL] [Abstract][Full Text] [Related]
15. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631 [TBL] [Abstract][Full Text] [Related]
16. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Martelli AM; Evangelisti C; Chiarini F; McCubrey JA Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809 [TBL] [Abstract][Full Text] [Related]
17. Recent clinical trials of mTOR-targeted cancer therapies. Don AS; Zheng XF Rev Recent Clin Trials; 2011 Jan; 6(1):24-35. PubMed ID: 20868343 [TBL] [Abstract][Full Text] [Related]
18. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Hidalgo M; Rowinsky EK Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655 [TBL] [Abstract][Full Text] [Related]
19. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas. Mita MM; Gong J; Chawla SP Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829 [TBL] [Abstract][Full Text] [Related]
20. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]